Press Releases

28/02/2024 OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership On February 28, 2024, at 6:00 p.m. CET / 12:00 a.m. ET.

28/02/2024 AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation

26/02/2024 OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

19/01/2024 OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook

11/12/2023 OSE Immunotherapeutics and Nantes University Hospital Present Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

21/11/2023 OSE Immunotherapeutics Announces a Collaboration Agreement with GenDx for the Development of a Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi®

23/10/2023 OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody

16/10/2023 OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors

27/09/2023 OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update

20/09/2023 OSE Immunotherapeutics Updates on its Research Programs in Presentations Selected for Upcoming International Conferences

11/09/2023 OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology

02/08/2023 OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics

12/07/2023 OSE Immunotherapeutics Announces Publication in Frontiers in Immunology on OSE-230, its Novel Agonist Therapy in Chronic Inflammation

11/07/2023 OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation

06/07/2023 OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist: Positive Review from the Drug Safety Monitoring Board (DSMB) on the Ongoing Phase 2 Clinical Trial in Ulcerative Colitis; Positive Opinion for Orphan Drug Designation from the European Medicines Agency in the Treatment of Acute Lymphoblastic Leukemia.

04/07/2023 OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment

22/06/2023 OSE Immunotherapeutics Reports on its 2023 Combined General Shareholder’s Meeting

20/06/2023 OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer

1 2 3 4 5 6 7 8 9 10 11